Last reviewed 2026-05-20 · How we verify

Menetryl (ETAFEDRINE)

Phase 2 active Small molecule ✓ Verified May 2026

Menetryl (generic name: ETAFEDRINE) is a etafedrine drug. It is currently in Phase 2 development.

Menetryl works by increasing the release of certain neurotransmitters in the body.

Menetryl, also known as etafedrine hydrochloride, is a small molecule medication.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETAFEDRINE
Drug class	etafedrine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with different neighborhoods, and neurotransmitters are the messengers that help different neighborhoods communicate with each other. Menetryl helps increase the number of these messengers, allowing different neighborhoods to talk to each other more effectively. This can help improve various bodily functions, such as heart rate and blood pressure.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Menetryl CI brief — competitive landscape report
Menetryl updates RSS · CI watch RSS

Frequently asked questions about Menetryl

What is Menetryl?

Menetryl (ETAFEDRINE) is a etafedrine drug.

How does Menetryl work?

Menetryl works by increasing the release of certain neurotransmitters in the body.

What is the generic name of Menetryl?

ETAFEDRINE is the generic (nonproprietary) name of Menetryl.

What drug class is Menetryl in?

Menetryl belongs to the etafedrine class. See all etafedrine drugs at /class/etafedrine.

What development phase is Menetryl in?

Menetryl is in Phase 2.

Drug class: All etafedrine drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing